Drug Trial Radar · NCT06013969
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Oct 22, 2023
Primary completion
May 13, 2026
Study completion Sep 2, 2026
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Boehringer Ingelheim
- First posted
- Aug 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated flares of GPP. The purpose of this study is to find out whether a medicine called spesolimab helps people with repeated flares of GPP. Participants are given a single dose of spesolimab as an infusion into a vein on the first day of an outbreak of GPP. They may be given a second dose 1 week later if doctors think it is helpful. They are also treated for additional GPP flares. During the time of the study, doctors regularly examine participants' skin for signs of GPP to see how well the treatment works and take blood samples. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Generalized Pustular Psoriasis
Interventions
SpesolimabDrug
Spesolimab intravenous (i.v.) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement of a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation sub-score of 0 indicating no visible pustules at Week 1Time frame: Up to week 1
Locations
35 sites in 17 countries. Site status is shown where the registry gives one.
University of California Irvine
Irvine, California
Red River Research Partners, LLC
Fargo, North Dakota
Liverpool Hospital
Liverpool, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hospital Universitario Evangelico Mackenzie
Curitiba, Brazil
Faculdade de Medicina do ABC
Santo André, Brazil
Southern Medical University Dermatology Hospital
Guangzhou, China
Shanghai Skin Disease Hospital
Shanghai, China
Shanghai Tenth People's Hospital
Shanghai, China
HOP Trousseau
Chambray-lès-Tours, France
HOP Saint-Louis
Paris, France
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Klinikum der Universität München AÖR
München, Germany
SP medical college and associated group of hospitals
Bikaner, India
Nkp Salve Institute of Medical Sciences and Lata Mangeshkar Hospital
Nagpur, India
ASST degli Spedali Civili di Brescia
Brescia, Italy
Hospital Selayang
Batu Caves, Malaysia
Hospital Pulau Pinang-Pulau Pinang-21953
Georgetown Pulau Pinang, Malaysia
Hospital Sultanah Aminah
Johor Bahru, Malaysia
Hospital Sultan Ismail
Johor Bahru, Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
Hospital Putrajaya
Putrajaya, Malaysia
Sunway Medical Centre
Selangor Darul Ehsan, Malaysia
National University Hospital-Singapore-42005
Singapore, Singapore
Nelson Mandela Academic Clinical Research Unit (NeMACRU)
Mthatha, Eastern Cape, South Africa
Seoul National University Hospital
Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramon Y Cajal
Madrid, Spain
National Taiwan University Hospital
Taipei, Taiwan
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taiwan
Srinagarind Hospital
Khon Kaen, Thailand
Maharat Nakhonchiangmai Hospital
Muang Chiang Mai, Thailand
Hedi Chaker Hospital, Department of Dermatology
Sfax, Tunisia
Farhat Hached Hospital
Sousse, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.